Navigation Links
Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
Date:3/31/2008

to continue as a "going concern."

Commenting further, Andrews said, "Given the current uncertainty surrounding the credit markets and our need for access to working capital to support our continued rapid growth, we were pleased to gain access to the capital necessary to enable us to continue to execute our plan. The new Safeguard credit line, along with our renewed facility with Comerica Bank, puts us on solid financial footing from which we can embark on the launch of our new breast cancer test. Based on our improvement in gross margins in 2007, our current commercial growth and our ongoing expense management, we believe we should be able to reduce our operating losses during 2008, which in turn should reduce the amount of additional funds we will need to draw from our newly negotiated line of credit."

The financial results described above reflect the impact of the adjustment to bad debt expense described above, as well as an aggregate $950,000 adjustment to reduce revenue (and record a corresponding liability) that the Company has made to its consolidated financial statements (allocated over a period of multiple quarters) resulting from the Company's analysis of financial information provided to the Company from its third party billing vendor relating to certain credit balances. As a result of matters identified in connection with the Company's year-end financial statement preparation process, management has identified material weaknesses in the Company's internal control over financial reporting. Additional details relating to these material weaknesses and the above-referenced adjustments will be included in the Company's Form 10-K for the fiscal year ended December 31, 2007 to be filed with the Securities and Exchange Commission.

Clarient will discuss fourth quarter 2007 results and certain future expectations on a conference call and live web cast at 8:00 a.m. EDT today. Call information is available at

SOURCE Clarient, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
2. Clarient to Commercialize Novel Breast Cancer Profile
3. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... The synthetic rubber ... get such derivatives as ethylbenzene, a precursor to styrene, used to make styrene-butadiene ... industry for the production of tyres and other components. Thus, growth in the ...
(Date:8/3/2015)... Md. , Aug. 3, 2015   Intrexon ... will release first half and second quarter 2015 financial ... th , 2015.  The Company will host a conference ... and provide a general business update. The ... US) and 1-412-902-4262 (International), and asking to join the ...
(Date:7/31/2015)... Texas (PRWEB) , ... July 31, 2015 , ... ... report, offering competitive market analysis and premium industry insights on the global resorcinol ... based on a collective study of vivid market scenarios and analysis of primary ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
Breaking Biology Technology:World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2
... top line data from a Phase 2 clinical trial ... of Influenza-Like Illness (ILI) caused by all types and ... strains. In a double-blind, placebo-controlled, Phase 2 trial of ... DAS181 resulted in a significant reduction in patients, influenza ...
... (July 1, 2011) After Fukushima, it is now imperative ... from cradle to grave. If nuclear waste management is not ... will reject nuclear power as an energy choice, according to ... Atomic Scientists , published by SAGE. According to Allison ...
... just fifteen minutes to analyze a sample suspected of ... The technology amplifies any anthrax DNA present in the ... microscopic cells of the deadly bacteria Bacillus anthracis. ... lethal microbe that might be used intentionally to infect ...
Cached Biology Technology:NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 2NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 3NexBio Reports Safety and Significant Antiviral Activities of DAS181 (Fludase)* from a Dose-Ranging Phase II Clinical Trial 4Nuclear waste requires cradle-to-grave strategy 2Nuclear waste requires cradle-to-grave strategy 3Nano detector for deadly anthrax 2
(Date:7/31/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY MANAGEMENT METHOD ... to advance crypto-currencies such as Bitcoin into the consumer ... way to manage all payments.  The ...
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/23/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ) has ... of the Biometrics Industry 2015 " report ... biometrics market is likely to witness significant growth ... the uptake of multiple technologies available. The year ... growth of biometrics in existing applications as well ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... This is the impressive result of a study carried out ... De Simoni of the Mario Negri Institute in Milan, Italy ... University of Lausanne. The study appears in the April 18th ... Public Library of Science, PLoS ONE. , Stroke is the ...
... years, ecologists from the Centre of Environment and Hydrology ... Lycaenid butterfly whose caterpillars live as parasites inside colonies ... the nurse ants. One of the peculiar features of ... the caterpillars complete development within one year. The rest ...
... Jan. 23 State of the Union address, President George Bush ... oil by requiring the production of 35 billion gallons a ... times the current target set by Congress of 7.5 billion ... fuels derived from biological material. Currently, the main biofuel used ...
Cached Biology News:Some caterpillers just don't want to grow up 2Cellulosic ethanol: Fuel of the future? 2Cellulosic ethanol: Fuel of the future? 3
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,448-8) ...
... Adept CE 4100 high pressure dual piston ... one microlitre increaments. The ground breaking ... flexibility. The WaveQuest provides a ... and provides superior stability . Hence ...
... of large numbers of samples may be carried ... minimum operator attention. System control and data ... CE 4900. The elegant, powerful and very ... and Windows 98 and 2000., The supplied detector ...
...
Biology Products: